AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05608720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Booklet
Description: Information Booklet prior to the dental visit
Study NCT00396227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: vildagliptin as add-on to metformin
Study NCT00396227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazolidinedione (TZD)
Description: TZD add-on to metformin
Study NCT01951482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/cisplatin
Description: receive Pemetrexed/cisplatin every 21 days
Study NCT01951482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Pemetrexed/cisplatin
Description: receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
Study NCT03468023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short arm cast
Description: Application of a below-elbow cast
Study NCT03468023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long arm cast
Description: Application of an above-elbow cast
Study NCT01004146 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Incentive Spirometry
Description: helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
Study NCT01004146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry
Description: helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
Study NCT01245894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Rosuvastatin
Description: Rosuvastatin 5mg/day for one year
Study NCT01245894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose Rosuvastatin
Description: Rosuvastatin 40mg/day for one year
Study NCT03403101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA > 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle.
Study NCT03403101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle
Study NCT03403101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle
Study NCT03647943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
Study NCT03647943 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
Study NCT03959618 — intervention group
Intervention type: OTHER
Intervention: dietary supplements questionary
Description: Patient Questionary Patient to be carried out at the last cure
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00400946 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00400946 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02783846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive equal volume of normal saline
Study NCT02030535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: free combination with tiotropium
Study NCT02783846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 0.5 µg/kg
Description: receive dexmedetomidine 0.5 µg/kg
Study NCT01176851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Single administration of Glyco pMDI 100 µg
Study NCT01176851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Single administration of Glyco pMDI 100 µg after charcoal ingestion
Study NCT01176851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Single intravenous injection of glycopyrrolate 100 µg
Study NCT02125929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
Study NCT02125929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
Study NCT02125929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
Study NCT01666873 — intervention group
Intervention type: PROCEDURE
Intervention: patients that undergo a total knee prosthesis
Study NCT02296840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 10mg/kg/day every 6-8 hours
Study NCT02296840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
Study NCT01873742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STIC feedback system
Description: This condition includes the use of the STIC feedback system.
Study NCT03558321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic guided fractional curretage
Description: Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
Study NCT03558321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection
Description: Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
Study NCT02612077 — intervention group
Intervention type: OTHER
Intervention: Observational Chemotherapy
Description: No intervention - Observational standard practice chemotherapy
Study NCT02612077 — intervention group
Intervention type: DRUG
Intervention: Concomitant Bevacizumab
Description: No intervention - Observational concomitant bevacizumab
Study NCT02461732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)
Description: Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings
Study NCT02461732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Substance Dependence
Description: Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities
Study NCT00349791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone (300 mcg/day) patch replaced twice a week for two years
Study NCT00349791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch replaced twice a week for two years
Study NCT02974946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard
Study NCT02575313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Food Intervention
Description: A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
Study NCT03939130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Consumption of 1.0g / kg of body mass / day of fructose.
Study NCT03939130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Consumption of 1.0g / kg of body mass / day of glucose.
Study NCT03939130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose and exercise
Description: Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
Study NCT03120403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Study NCT01985685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: 200 mg IV thiamine
Study NCT01985685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 200 mg IV thiamine
Study NCT03330743 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Mentor with Standard Education
Description: Parent mentors will provide coaching based on the current guidelines around diet and physical activity
Study NCT03330743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Mentor with Positive Deviance
Description: Parent mentors will provide coaching based on findings from the positive deviance study
Study NCT00607828 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo radiotherapy
Study NCT01863563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickClot
Description: 1 application of treatment to each tonsil/adenoid removal area
Study NCT02030535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: free combination with olodaterol
Study NCT02030535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02030535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination with olodaterol
Study NCT02030535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination with tiotropium
Study NCT05937126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FilmArray Pneumonia Panel
Description: FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
Study NCT05937126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Culture and antimicrobial susceptibility testing
Description: Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
Study NCT04151368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Nipple-Sparing Mastectomy (RNSM)
Description: RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
Study NCT00078923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Study NCT00078923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Prostatectomy or Brachytherapy
Study NCT00078923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
Study NCT03891095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasally administrated
Study NCT03891095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA
Description: orally administered
Study NCT03891095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: intranasally administrated and orally administered
Study NCT03891095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: intranasally administrated and orally administered
Study NCT02783846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 1.0 µg/kg
Description: receive dexmedetomidine 1.0 µg/kg
Study NCT00970866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron and Folic Acid (IFA)
Description: Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
Study NCT00970866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Micronutrient (MMN) group
Description: Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
Study NCT00970866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid-based Nutrient Supplements (LNS) group
Description: Pregnant women will receive 20 g of LNS-P\&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P\&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (\~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration.
Study NCT00637871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: 150mg once daily
Study NCT00637871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Study NCT04208581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Huatan granule
Description: Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
Study NCT04208581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Yiqi Huoxue Huatan granule
Description: Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
Study NCT05541068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance analysis
Description: Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
Study NCT01732003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete
Study NCT01732003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Study NCT03129256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate tablet combined with S-1 capsules
Description: Oral use with low-dose Apatinib combined with S-1 until disease progression
Study NCT03457194 — intervention group
Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine
Description: Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
Study NCT03457194 — intervention group
Intervention type: BIOLOGICAL
Intervention: DTP Vaccine (Multiple Actives)
Description: Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
Study NCT03914339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal and orthodontic treatment
Description: Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
Study NCT00443430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
Study NCT00443430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate - etanercept - prednisolone arm
Description: methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
Study NCT00107263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT03391440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morinidazole
Description: morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
Study NCT03995407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peptamen®
Description: Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
Study NCT03995407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations.
Study NCT02408146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional intravenous infusion pump
Description: The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
Study NCT02408146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.